Extracellular vesicles as therapeutic agents in rheumatoid arthritis: a systematic review of current evidence

被引：0
作者：
Miao, Xiaolei [1 ]
Ghafourian, Amirreza [2 ]
Khaneghah, Mahdi Karimi [3 ]
Ayyoubzadeh, Seyed Mohammad [4 ,5 ]
Afrisham, Reza [2 ]
Ahmadi, Mahnaz [6 ]
机构：
[1] Hubei Univ Sci & Technol, Xianning Med Coll, Hubei Key Lab Diabet & Angiopathy, Sch Pharm, Xianning 437100, Hubei, Peoples R China
[2] Univ Tehran Med Sci, Sch Allied Med Sci, Dept Med Lab Sci, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmaceut & Pharmaceut Nanotechnol, Tehran, Iran
[4] Univ Tehran Med Sci, Sch Allied Med Sci, Dept Hlth Informat Management, Tehran, Iran
[5] Univ Tehran Med Sci, Hlth Informat Management Res Ctr, Tehran, Iran
[6] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran, Iran
来源：
INFLAMMOPHARMACOLOGY | 2025年 / 33卷 / 03期
关键词：
Extracellular vesicles; Exosomes; rheumatoid arthritis; Mesenchymal stem cells; Systematic review; MESENCHYMAL STEM-CELLS; FIBROBLAST-LIKE SYNOVIOCYTES; COLLAGEN-INDUCED ARTHRITIS; DENDRITIC CELLS; EXOSOMES; INFLAMMATION; STRATEGIES;
D O I：
10.1007/s10787-025-01670-9
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Rheumatoid arthritis (RA) is defined as a chronic autoimmune disease that severely influences a patient's quality of life. Extracellular vesicles (EVs) have gained much attention in recent years as one of the most potent therapeutic agents for the treatment of RA. A systematic review was performed with the purpose of assessing the current evidence relating to the therapeutic applications of EVs in RA. The systematic search was performed in the databases of PubMed, Scopus, and Web of Science, from inception times to September 2024. All studies investigating the use of EVs for the treatment of RA were included. The quality appraisal of selected articles and data extraction regarding EV characteristics, therapeutic applications, and associated outcomes were performed. Of the 1418 initially identified articles, 59 studies met inclusion criteria. Regarding their cellular origins, most EVs were derived from mesenchymal stem cells, followed by immune cells. The main therapeutic mechanisms included modulation of the immune response, reduction of inflammation, and repair of tissues. Recent trends are toward increasing interest in engineered EVs and combination therapies. Indeed, most studies reported positive outcomes with regard to lowered inflammation and improved joint function. On the other hand, standardization of the metrics of evaluation considerably varied between different studies. EVs are promising therapeutic agents in the treatment of RA by modulating immune responses. Standardization, delivery systems, and clinical translation are challenges yet to be overcome. Future studies will be directed to optimize EV engineering, targeted delivery systems, and large-scale clinical trials.
引用
收藏
页码：889 / 915
页数：27
相关论文
共 82 条
  • [1] Arntz O.J., Pieters B.C., Oliveira M.C., Broeren M.G., Bennink M.B., de Vries M., van Lent P.L., Koenders M.I., van den Berg W.B., van der Kraan P.M., Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models, Mol Nutr Food Res, 59, 9, pp. 1701-1712, (2015)
  • [2] Arntz O., Pieters B., Thurlings R., Wenink M., van Lent P., Koenders M., van den Hoogen F., van der Kraan P., van de Loo F., Rheumatoid arthritis patients with circulating extracellular vesicles positive for igm rheumatoid factor have higher disease activity, Front Immunol, 2018, 9, (2018)
  • [3] Bakinowska E., Kielbowski K., Pawlik A., The role of extracellular Vesicles in the pathogenesis and treatment of rheumatoid arthritis and osteoarthritis, Cells, 12, 23, (2023)
  • [4] Bianco N.R., Kim S.H., Ruffner M.A., Robbins P.D., Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase–positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models, Arthritis Rheumatism, 60, 2, pp. 380-389, (2009)
  • [5] Bruckner S., Capria V.M., Zeno B., Leblebicioglu B., Goyal K., Vasileff W.K., Awan H., Willis W.L., Ganesan L.P., Jarjour W.N., The therapeutic effects of gingival mesenchymal stem cells and their exosomes in a chimeric model of rheumatoid arthritis, Arthritis Res Ther, 25, 1, (2023)
  • [6] Burmester G.R., Pope J.E., Novel treatment strategies in rheumatoid arthritis, The Lancet, 389, pp. 2338-2348, (2017)
  • [7] Casado J.G., Blazquez R., Vela F.J., Alvarez V., Tarazona R., Sanchez-Margallo F.M., Mesenchymal stem cell-derived exosomes: immunomodulatory evaluation in an antigen-induced synovitis porcine model, Front Veterinary Sci, 4, (2017)
  • [8] Chang L., Kan L., Mesenchymal stem cell-originated exosomal circular RNA circFBXW7 attenuates cell proliferation, migration and inflammation of fibroblast-like synoviocytes by targeting miR-216a-3p/HDAC4 in rheumatoid arthritis, J Inflamm Res, 14, pp. 6157-6171, (2021)
  • [9] Chen Z., Wang H., Xia Y., Yan F., Lu Y., Therapeutic potential of mesenchymal cell–derived miRNA-150-5p–expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF, J Immunol, 201, 8, pp. 2472-2482, (2018)
  • [10] Chen J., Liu M., Luo X., Peng L., Zhao Z., He C., He Y., Exosomal miRNA-486-5p derived from rheumatoid arthritis fibroblast-like synoviocytes induces osteoblast differentiation through the Tob1/BMP/Smad pathway, Biomater Sci, 8, 12, pp. 3430-3442, (2020)
123456789